General form of registration statement for all companies including face-amount certificate companies

License Agreements - Additional Information (Detail)

v3.3.1.900
License Agreements - Additional Information (Detail)
 6 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Dec. 31, 2015
GBP (£)
Dec. 15, 2015
USD ($)
Dec. 15, 2015
GBP (£)
Dec. 14, 2015
USD ($)
Oct. 16, 2012
USD ($)
Nov. 30, 2015
USD ($)
Nov. 30, 2015
GBP (£)
May. 31, 2015
USD ($)
May. 31, 2015
GBP (£)
Jun. 30, 2016
USD ($)
Jun. 30, 2016
GBP (£)
Jan. 08, 2016
USD ($)
Nov. 30, 2015
GBP (£)
Commitments and Contingencies [Line Items]                            
Asset purchase, cash paid           $ 3,500,000                
Asset Purchase Agreement Aggregate Consideration Paying Period             10 years 10 years 10 years 10 years        
Accrued milestone payments             $ 2,500,000   $ 2,500,000          
Maximum contingent payment             930,000             £ 600,000
Accrued license fees             $ 1,860,000   $ 930,000          
Annual license fee | £               £ 300,000   £ 300,000        
Progenics Pharmaceuticals, Inc.                            
Commitments and Contingencies [Line Items]                            
Royalty on every net sales                 5.00%          
Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Royalty on every net sales             5.00%             5.00%
Development Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Royalty on every net sales                 7.50%          
Asset Purchase Agreement Aggregate Consideration Paying Period             10 years 10 years 10 years 10 years        
Minimum annual license maintenance fees             $ 150,000   $ 150,000          
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Payment to acquire other assets             1,500,000   1,500,000          
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Payment to acquire other assets             1,000,000   1,000,000          
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Payment to acquire other assets             $ 5,000,000   5,000,000          
First US new drug application approval by the FDA or other non-U.S. approval | Development Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Payment to acquire other assets                 500,000          
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Payment to acquire other assets                 $ 500,000          
Royalty on every net sales             7.50%             7.50%
Scenario, Forecast                            
Commitments and Contingencies [Line Items]                            
License payment $ 930,000 £ 600,000                        
Maximum contingent payment                     $ 930,000 £ 600,000    
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments                            
Commitments and Contingencies [Line Items]                            
Payment to acquire other assets             $ 500,000              
Subsequent Event                            
Commitments and Contingencies [Line Items]                            
Accrued milestone payments                         $ 1,500,000  
License payment     $ 915,000 £ 600,000 $ 915,000